Cases: alloantibody formers Controls: non-alloantibody formers

Blood samples from consenting participants collected and retained: plasma,serum and buffy coat

Hemolysis

Leiden University Medical Center

R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions

Outcome measure would be assessed in a participating study center after an average 8 weeks from the initiation of the study in that particular study center

Sanquin Research & Blood Bank Divisions

Infection, Bacterial

Antibiotic Resistant Infection

Diagnostic Self Evaluation

Meningitis, Bacterial

Nosocomial Infection

Neurosurgery dept. University Hospital

Neurosurgery department, University Hospital

Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients.

analyse of different body fluids to detect the focus of infections post neurosurgical fever

Fariba Nayeri

MD, PhD, associated professor

70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)

70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.

Induction of Labor Affected Fetus / Newborn

Rupture of Membranes Prior to Onset of Labor

70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM) repeated every 4 hours maximum 4 times

isosorbide mononitrate

70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.repeated every 4 hours maximum 4 times

Placebo

faculty of medicine - Cairo university

Nitric Oxide Donor Isosorbide Mono Nitrate for Induction of Labor With Pre-labor Rupture of Membranes

Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor in Term or Post Term Pregnancies in Females With Pre-labor Rupture of Membranes

the effectiveness and safety of vaginal administration of isosorbide mono nitrate (IMN) to induce cervical ripening for induction of labor at term or post term pregnancy with prelabor rupture of membrane regarding (Induction to onset of labor time, Induction to delivery time)

ahmed nagy shaker ramadan

resident of obstetrics and gynecology

The patients will be divided into 2 groups:
Group 1:
70 pregnant females, induction of labor will be done by Intra vaginal isosorbide mono nitrate (Effox 40 mg MINAPHARM)
Group 2:
70 pregnant females, induction will be done by placebo (pyridoxine) administered in the posterior vaginal fornix.

A double-blind study is one in which neither the participants nor the experimenters know who is receiving a particular treatment. This procedure is utilized to prevent bias in research results. Double-blind studies are particularly useful for preventing bias due to demand characteristics or the placebo effect. In a double-blind study, the investigators who interact with the participants would not know who was receiving the actual drug and who was receiving a placebo.

Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours or standard care. Viusid and Asbrip will be administered orally.
A total of 60 subjects will be randomized 2: 1 in this study. 40 patients will be assigned to Viusid plus Asbrip plus standard of care.
Treatment duration: 21 days.

A total of 60 subjects will be randomized 2: 1 in this study. 20 Control patients will be assigned to standard of care.
Treatment duration: 21 days.

Covid-19

Sars-CoV2

Diabete Mellitus

Cardiopathy

Pulmonary Disease

Renal Disease

Liver Diseases

Patients will be randomized to receive daily doses of 30 ml of Viusid and 10 ml of Asbrip every 8 hours plus standard care. Viusid and Asbrip will be administered orally.
Treatment duration: 21 days.

Viusid and Asbrip

Hospital de Especialidades Dr. Teodoro Maldonado Carbo

Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19

Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients in Teodoro Maldonado Carbo Specialty's Hospital Infected and Diagnosed by SARS-Cov-2 With COVID-19

The number of days required to achieve a score of 0 for each symptom category.
Resolution of symptoms: fever (time frame: 21 days) Fever based on a 0-3 scale: 0 = ≤98.6, 1 => 98.6- 100.6, 2 => 100.6 - 102.6, 3 => 102.6
Resolution of symptoms: cough (time frame: 21 days) Cough based on a 0-3 scale: 0 = no cough, 1 = mild, 2 = moderate, 3 = severe
Resolution of symptoms: shortness of breath (time frame: 21 days) Shortness of breath based on a 0-3 scale: 0 = no shortness of breath, 1 = with moderate intensity exercise 2 = walking on a flat surface 3 = shortness of breath when dressing or doing daily activities
Resolution of symptoms: fatigue (period: 21 days) Fatigue based on a 0-3 scale: 1 = mild fatigue, 2 = moderate fatigue, 3 = severe fatigue.
Composite score that includes all symptoms: (time frame: 21 days) Total composite score of symptoms on days 5, 10, 15, and 21 of study supplementation.

Disease severity will be measured using a disease severity clinical event scale (assessed until day 21) Change from baseline in the patient's health status on an ordinal scale of 7 categories (time frame: days 3, 7, 14, 21)
death
Hospitalized, with invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
Hospitalized, with non-invasive ventilation or high-flow oxygen devices
Hospitalized, requiring supplemental oxygen
Hospitalized, which does not require supplemental oxygen
Not hospitalized, limitation of activities.
Not hospitalized, without limitations in activities. Note: lower scores mean a worse result.

Differences in the number of patients who received complementary medications for diagnosis between the study arms.

Differences in the number of patients in the study groups experiencing side effects of the supplements.

PCR analysis at day 0, 7th, 14th and 21th to measure and compare viral load

Blood biochemical analysis at day 0, 3rd, 7th, 14th and 21th

Number of Incidences of mechanical ventilation supply per patient

Number of days with mechanical ventilation supply

Number of days patient need to recover from disease

Change from baseline in serum cytokine IL-1 level by blood biochemical analysis at day 0, 3, 7, 14 and 21

Change from baseline in serum cytokine IL-6 level by blood biochemical analysis at day 0, 3, 7, 14 and 21

Change from baseline in serum cytokine TNF-α level by blood biochemical analysis at day 0, 3, 7, 14 and 21

Change from baseline in CCR5 receptor occupancy levels for Tregs and macrophages by blood biochemical analysis at day 0, 3, 7, 14 and 21

Change from baseline in CD3 +, CD4 + and CD8 + T cell counts by blood biochemical analysis at day 0, 3, 7, 14 and 21.

Change in liver function test (AST, ALT and TBIL) by blood biochemical analysis at day 0, 4, 7, 14 and 21.

Change in kidney function with eGFR rate by blood and urinary biochemical analysis at day 0, 4, 7, 14 and 21.

Change in kidney function with creatine clearance rate by blood and urinary biochemical analysis at day 0, 4, 7, 14 and 21.

Change in routine blood test red blood cells concentration by blood biochemical analysis at day 0, 4, 7, 14 and 21.

Change in routine blood test white blood cell concentration by blood biochemical analysis at day 0, 4, 7, 14 and 21.

Change in routine blood test D-dimer level by blood biochemical analysis at day 0, 4, 7, 14 and 21.

Change in routine blood test fibrinogen level by blood biochemical analysis at day 0, 4, 7, 14 and 21.

Change in myocardial enzyme CPK-MB by blood biochemical analysis at daty 0, 4, 7, 14 and 21

Change in myocardial enzymes troponins by blood biochemical analysis at daty 0, 4, 7, 14 and 21

bola/ethet

R-FACT Study:Risk Factors for Alloimmunization After Red Blood Cell Transfusions

Rapid Test for Detection of the Focus of Infection in Post Neurosurgical Patients.

Nitric Oxide Donor Isosorbide Mono Nitrate for Induction of Labor With Pre-labor Rupture of Membranes

Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19

Baza e të dhënave më e plotë e bimëve medicinale e mbështetur nga shkenca